In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Neumora Therapeutics Inc (NASDAQ: NMRA) closed at $2.15 up 0.47% from its previous closing price of $2.14. In other words, the price has increased by $0.47 from its previous closing price. On the day, 0.61 million shares were traded. NMRA stock price reached its highest trading level at $2.22 during the session, while it also had its lowest trading level at $2.13.
Ratios:
For a deeper understanding of Neumora Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.85 and its Current Ratio is at 6.85. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on January 12, 2026, initiated with a Outperform rating and assigned the stock a target price of $8.
On December 01, 2025, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform but kept the price unchanged to $7.
Guggenheim Upgraded its Neutral to Buy on October 27, 2025, while the target price for the stock was maintained at $14.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 11 ’25 when Aurora Daljit Singh sold 114,703 shares for $2.68 per share. The transaction valued at 307,026 led to the insider holds 0 shares of the business.
Aurora Family Trust bought 114,703 shares of NMRA for $307,027 on Nov 11 ’25. On Oct 27 ’25, another insider, Burow Kristina, who serves as the Director of the company, bought 1,915,700 shares for $2.61 each. As a result, the insider paid 4,999,977 and bolstered with 6,046,907 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NMRA now has a Market Capitalization of 365367680 and an Enterprise Value of 207802592.
Stock Price History:
The Beta on a monthly basis for NMRA is 3.26, which has changed by -0.01382488 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, NMRA has reached a high of $3.25, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is -2.87%, while the 200-Day Moving Average is calculated to be 38.70%.
Shares Statistics:
For the past three months, NMRA has traded an average of 2.13M shares per day and 3395260 over the past ten days. A total of 161.95M shares are outstanding, with a floating share count of 57.94M. Insiders hold about 65.32% of the company’s shares, while institutions hold 18.65% stake in the company. Shares short for NMRA as of 1767139200 were 7502647 with a Short Ratio of 3.52, compared to 1764288000 on 6468823. Therefore, it implies a Short% of Shares Outstanding of 7502647 and a Short% of Float of 11.2399995.
Earnings Estimates
The firm’s stock currently is rated by 8.0 analysts. The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.26 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$1.35 and -$1.47 for the fiscal current year, implying an average EPS of -$1.43. EPS for the following year is -$0.98, with 8.0 analysts recommending between -$0.63 and -$1.45.
